In October 2008, beating out an earlier bid by Bristol-Myers Squibb, Imclone Systems Inc was acquired by Eli Lilly, and is now operating as a wholly-owned subsidiary of the larger firm. Imclone Systems is a biopharmaceutical company that is primarily engaged in the research and development of drugs and other products for the treatment of cancer and cancer-related disorders. The Company has three cancer-related products that are being developed, two of which are being tested in clinical trials. The Products are C225 Cancer Therapeutic, BEC2 Cancer Vaccine, and c-p1C11 Monoclonal Antibody Inhibitor of Angiogenesis. The Company also conducts research programs on developing inhibitors of tyrosine kinase receptors, a research on antibodies that inhibit vascular-specific cadherin (VE-cadherin) and researches on possible cancer vaccines. In addition, the Company has developed the technology necessary to isolate endothelial stem cells and is also conducting a research in hematopoiesis.
